<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21542887</article-id><article-id pub-id-type="pmc">3132047</article-id><article-id pub-id-type="publisher-id">ar3301</article-id><article-id pub-id-type="doi">10.1186/ar3301</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Response to 'Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months'</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Gonzalez-Gay</surname><given-names>Miguel A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>miguelaggay@hotmail.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Gonzalez-Juanatey</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>carlosjuanatey@secardiologia.es</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Miranda-Filloy</surname><given-names>Jose A</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jose.alberto.miranda.filloy@sergas.es</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Martin</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>martin@ipb.csic.es</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Garcia-Unzueta</surname><given-names>Maria T</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>garciaunzueta@yahoo.es</email></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="A6"><name><surname>Llorca</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="I6">6</xref><xref ref-type="aff" rid="I7">7</xref><email>llorcaj@unican.es</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Rheumatology, Hospital Universitario Marqu&#x000e9;s de Valdecilla, Avenida de Valdecilla s/n, 39008-Santander, IFIMAV, Santander, Spain</aff><aff id="I2"><label>2</label>Division of Cardiology, Hospital Xeral-Calde, c) Dr. Ocha s/n, 27004-Lugo, Spain</aff><aff id="I3"><label>3</label>Division of Rheumatology, Hospital Xeral-Calde, c) Dr. Ocha s/n, 27004-Lugo, Spain</aff><aff id="I4"><label>4</label>Instituto de Parasitolog&#x000ed;a y Biomedicina L&#x000f3;pez-Neyra, Consejo Superior de Investigaciones Cient&#x000ed;ficas (C.S.I.C.), Parque Tecnol&#x000f3;gico de Ciencias de la Salud, Avda. del Conocimiento, s/n, 18100 Armilla, Granada, Spain</aff><aff id="I5"><label>5</label>Endocrinology Research Unit, Hospital Universitario Marqu&#x000e9;s de Valdecilla, Avenida de Valdecilla s/n, 39008-Santander, IFIMAV, Santander, Spain</aff><aff id="I6"><label>6</label>Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Avda. Herrera Oria s/n. 39011-Santander, Spain</aff><aff id="I7"><label>7</label>CIBER Epidemiolog&#x000ed;a y Salud P&#x000fa;blica (CIBERESP), IFIMAV, Spain</aff><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>27</day><month>4</month><year>2011</year></pub-date><!-- PMC Release delay is 6 months and 0 days and was based on the epub date.--><pub-date pub-type="pmc-release"><day>27</day><month>10</month><year>2011</year></pub-date><volume>13</volume><issue>2</issue><fpage>404</fpage><lpage>404</lpage><permissions><copyright-statement>Copyright &#x000a9;2011 BioMed Central Ltd</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>BioMed Central Ltd</copyright-holder></permissions><self-uri xlink:href="http://arthritis-research.com/content/13/2/404"/></article-meta></front><body><sec><title/><p>We read with great interest the study by Engvall and colleagues [<xref ref-type="bibr" rid="B1">1</xref>] in a recent issue of <italic>Arthritis Research &#x00026;</italic><italic>Therapy</italic>. The study showed that anti-tumor necrosis factor-alpha (anti-TNF-&#x003b1;) infliximab therapy is associated with an increase of body fat mass in early rheumatoid arthritis (RA) independently of changes in disease activity and levels of leptin and adiponectin.</p><p>With respect to this, we have prospectively followed a cohort of patients who had RA refractory to conventional disease-modifying ant rheumatic drugs, including methotrexate, and who, owing to disease severity, underwent anti-TNF-&#x003b1;-infliximab therapy. Among them, a subgroup of 33 consecutive RA patients who were on periodical treatment with infliximab and who agreed to participate in the study was assessed to determine the short- term effect of this drug on insulin resistance, ghrelin, and adipokine profile. Besides noting a dramatic improvement of insulin resistance following infliximab administration [<xref ref-type="bibr" rid="B2">2</xref>], we observed that, upon administration of this drug, serum ghrelin concentrations (in picograms per milliliter) increased significantly (896.1 &#x000b1; 314.8, median 861.2, interquartile range (IQR) 700.5 to 879.9 before infliximab at time 0 (baseline) and 976.3 &#x000b1; 373.0, median 905.8, IQR 752.6 to 1,152.8 after infliximab infusion at 120 minutes; <italic>P </italic>&#x0003c; 0.001) and that increases in ghrelin concentrations were associated with reductions in P-selectin concentrations (<italic>r </italic>= -0.513; <italic>P </italic>= 0.002) [<xref ref-type="bibr" rid="B3">3</xref>]. However, ghrelin concentrations were not related to the DAS28 (disease activity score using 28 joint counts), the mean erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) from disease diagnosis or the ESR, platelet count, CRP, or cumulative prednisone dose at the time of the study [<xref ref-type="bibr" rid="B3">3</xref>]. Moreover, we observed a significant correlation between leptin levels and body mass index [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Apart from stimulating growth hormone production, ghrelin regulates energy homeostasis through increasing food intake and decreasing fat utilization, leading to increased adiposity through growth hormone-independent mechanisms [<xref ref-type="bibr" rid="B5">5</xref>]. Ghrelin is further associated with metabolic syndrome features, and ghrelin administration has beneficial effects not only on cachexia in patients with heart failure and chronic obstructive pulmonary disease but also on insulin sensitivity in overweight patients and endothelial dysfunction in patients with metabolic syndrome [<xref ref-type="bibr" rid="B6">6</xref>]. Additionally, ghrelin has potent anti-inflammatory effects, including the inhibition of proinflammatory cytokine production by T lymphocytes and monocytes within the immune system and human endothelial cells [<xref ref-type="bibr" rid="B7">7</xref>]. Besides noting the rapid decrease of P-selectin, a biomarker of endothelial dysfunction [<xref ref-type="bibr" rid="B8">8</xref>], we observed a rapid and significant improvement of endothelial function following infliximab administration in these patients [<xref ref-type="bibr" rid="B9">9</xref>].</p><p>According to our observations, anti-TNF-&#x003b1; therapy increases serum levels of ghrelin. Since ghrelin has anti-inflammatory effects, increased levels presumably would be additive to the efficacious actions of infliximab [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Metabolic syndrome features are independently associated with atherosclerosis in RA [<xref ref-type="bibr" rid="B10">10</xref>]. However, in our series of patients with severe RA, in contrast to what was reported in non-RA subjects, metabolic syndrome features were not related to ghrelin concentrations [<xref ref-type="bibr" rid="B3">3</xref>]. It is possible that improvement of ghrelin metabolism through inhibition of cytokine production attenuates the cachexia in patients with RA. Additionally, in our series, we observed a significant increase of body mass index when values obtained before the onset of infliximab therapy were compared with those observed after 2 years of infliximab therapy (unpublished observations).</p><p>Considering all of these observations, we feel that, in patients with severe RA, the TNF-&#x003b1; blockade may improve the impaired production of ghrelin, a hormone that is implicated in RA-associated cachexia. This effect may lead to an increase of body mass index in RA patients undergoing TNF-&#x003b1; antagonist therapy.</p></sec><sec><title>Abbreviations</title><p>CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IQR: interquartile range; RA: rheumatoid arthritis; TNF-&#x003b1;: tumor necrosis factor-alpha.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec></body><back><sec><title>Acknowledgements</title><p>This work was supported by two grants from Fondo de Investigaciones Sanitarias, PI06-0024 and PS09/00748 (Spain), and in part by RETICS Program grant RD08/0075 (RIER) from Instituto de Salud Carlos III (ISCIII).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Engvall</surname><given-names>I-L</given-names></name><name><surname>Tengstrand</surname><given-names>B</given-names></name><name><surname>Brismar</surname><given-names>K</given-names></name><name><surname>Hafstr&#x000f6;m</surname><given-names>I</given-names></name><article-title>Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months</article-title><source>Arthitis Res Ther</source><year>2010</year><volume>12</volume><fpage>R197</fpage><pub-id pub-id-type="doi">10.1186/ar3169</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Gonzalez-Gay</surname><given-names>MA</given-names></name><name><surname>De Matias</surname><given-names>JM</given-names></name><name><surname>Gonzalez-Juanatey</surname><given-names>C</given-names></name><name><surname>Garcia-Porrua</surname><given-names>C</given-names></name><name><surname>Sanchez-Andrade</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><article-title>Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><year>2006</year><volume>24</volume><fpage>83</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">16539824</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Gonzalez-Gay</surname><given-names>MA</given-names></name><name><surname>Garcia-Unzueta</surname><given-names>MT</given-names></name><name><surname>Berja</surname><given-names>A</given-names></name><name><surname>Vazquez-Rodriguez</surname><given-names>TR</given-names></name><name><surname>Gonzalez-Juanatey</surname><given-names>C</given-names></name><name><surname>de Matias</surname><given-names>JM</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Dessein</surname><given-names>PH</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><article-title>Antitumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2008</year><volume>67</volume><fpage>1644</fpage><lpage>1646</lpage><pub-id pub-id-type="pmid">18854515</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Gonzalez-Gay</surname><given-names>MA</given-names></name><name><surname>Garcia-Unzueta</surname><given-names>MT</given-names></name><name><surname>Berja</surname><given-names>A</given-names></name><name><surname>Gonzalez-Juanatey</surname><given-names>C</given-names></name><name><surname>Miranda-Filloy</surname><given-names>JA</given-names></name><name><surname>Vazquez-Rodriguez</surname><given-names>TR</given-names></name><name><surname>de Matias</surname><given-names>JM</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Dessein</surname><given-names>PH</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><article-title>Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><year>2009</year><volume>27</volume><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">19473561</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Otto</surname><given-names>B</given-names></name><name><surname>Cuntz</surname><given-names>U</given-names></name><name><surname>Fruehauf</surname><given-names>E</given-names></name><name><surname>Wawarta</surname><given-names>R</given-names></name><name><surname>Folwaczny</surname><given-names>C</given-names></name><name><surname>Riepl</surname><given-names>RL</given-names></name><name><surname>Heiman</surname><given-names>ML</given-names></name><name><surname>Lehnert</surname><given-names>P</given-names></name><name><surname>Fichter</surname><given-names>M</given-names></name><name><surname>Tsch&#x000f6;p</surname><given-names>M</given-names></name><article-title>Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa</article-title><source>Eur J Endocrinol</source><year>2001</year><volume>145</volume><fpage>669</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1530/eje.0.1450669</pub-id><pub-id pub-id-type="pmid">11720888</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Kangawa</surname><given-names>K</given-names></name><article-title>Ghrelin, a novel growth hormonereleasing peptide, in the treatment of cardiopulmonary-associated cachexia</article-title><source>Intern Med</source><year>2006</year><volume>45</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.45.1402</pub-id><pub-id pub-id-type="pmid">16508225</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>WG</given-names></name><name><surname>Gavrila</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gunnlaugsson</surname><given-names>S</given-names></name><name><surname>Stoll</surname><given-names>LL</given-names></name><name><surname>McCormick</surname><given-names>ML</given-names></name><name><surname>Sigmund</surname><given-names>CD</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Weintraub</surname><given-names>NL</given-names></name><article-title>Ghrelin inhibits proinflamatory responses and nuclear factor-kappaB activation in human endothelial cells</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>2221</fpage><lpage>2226</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000127956.43874.F2</pub-id><pub-id pub-id-type="pmid">15117840</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Gonzalez-Gay</surname><given-names>MA</given-names></name><name><surname>Garcia-Unzueta</surname><given-names>MT</given-names></name><name><surname>De Matias</surname><given-names>JM</given-names></name><name><surname>Gonzalez-Juanatey</surname><given-names>C</given-names></name><name><surname>Garcia-Porrua</surname><given-names>C</given-names></name><name><surname>Sanchez-Andrade</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><article-title>Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><year>2006</year><volume>24</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">16956426</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Gonzalez-Juanatey</surname><given-names>C</given-names></name><name><surname>Testa</surname><given-names>A</given-names></name><name><surname>Garcia-Castelo</surname><given-names>A</given-names></name><name><surname>Garcia-Porrua</surname><given-names>C</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><name><surname>Gonzalez-Gay</surname><given-names>MA</given-names></name><article-title>Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody</article-title><source>Arthritis Rheum</source><year>2004</year><volume>51</volume><fpage>447</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1002/art.20407</pub-id><pub-id pub-id-type="pmid">15188332</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Dessein</surname><given-names>PH</given-names></name><name><surname>Tobias</surname><given-names>M</given-names></name><name><surname>Veller</surname><given-names>MG</given-names></name><article-title>Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis</article-title><source>J Rheumatol</source><year>2006</year><volume>33</volume><fpage>2425</fpage><lpage>2452</lpage><pub-id pub-id-type="pmid">17080519</pub-id></mixed-citation></ref></ref-list></back></article>